MusclePharm (MSLP) stock price, revenue, and financials

MusclePharm market cap is $3.3 m, and annual revenue was $79.67 m in FY 2019

$3.3 M

MSLP Mkt cap, 16-Sept-2020

$79.7 M

MusclePharm Revenue FY, 2019
MusclePharm Gross profit (FY, 2019)8.7 M
MusclePharm Gross profit margin (FY, 2019), %10.9%
MusclePharm Net income (FY, 2019)-18.9 M
MusclePharm EBIT (FY, 2019)-15.1 M
MusclePharm Cash, 31-Dec-20191.5 M
MusclePharm EV13.3 M

MusclePharm Revenue

MusclePharm revenue was $79.67 m in FY, 2019

Embed Graph

MusclePharm Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

3.8m4.4m16.6m15.4m18.6m22.6m25.5m25.3m50.2m47.8m41.3m50.5m34.0m42.9m32.9m30.7m26.0m26.2m24.4m26.5m27.1m27.4m18.8m22.3m21.2m

Cost of goods sold

2.5m3.9m12.9m12.9m14.5m14.4m17.6m17.9m32.3m31.1m32.8m26.9m33.0m23.5m27.7m22.2m20.5m19.5m18.6m16.4m18.3m19.0m18.6m15.9m20.6m19.6m

Gross profit

1.3m514.9k3.7m2.5m4.1m8.2m7.9m7.4m17.9m15.0m14.4m17.5m10.5m15.2m10.7m10.2m6.5m7.6m8.0m8.2m8.2m8.8m2.9m1.7m1.5m

Gross profit Margin, %

35%12%22%16%22%36%31%29%36%31%35%35%31%35%33%33%25%29%33%31%30%32%16%8%7%

Sales and marketing expense

2.0m2.6m2.3m4.0m6.3m5.8m7.7m7.2m8.3m7.1m4.3m2.7m1.9m1.9m2.2m2.0m3.7m5.0m3.6m751.0k809.0k574.0k

R&D expense

1.1m1.2m735.5k965.0k921.0k1.4m863.0k531.0k270.0k137.0k152.0k199.0k212.0k208.0k185.0k247.0k215.0k232.0k

General and administrative expense

3.2m2.9m4.4m4.2m7.9m8.9m10.7m1.9m1.9m3.7m5.0m5.1m4.6m4.2m4.4m3.9m2.9m2.8m3.5m2.5m2.7m3.0m2.6m2.4m1.9m

Operating expense total

3.2m2.9m4.4m4.2m7.9m8.9m10.7m12.3m15.4m15.2m19.5m21.7m24.2m37.5m21.0m12.2m11.5m9.1m10.0m9.3m9.1m8.0m9.8m6.2m6.6m5.6m

Depreciation and amortization

100.0k100.0k

EBIT

(1.9m)(2.4m)(727.3k)(1.7m)(3.8m)(721.5k)(2.7m)(4.9m)2.4m479.5k(4.5m)(7.3m)(6.7m)(27.0m)(5.8m)(1.5m)(1.3m)(2.6m)(2.4m)(1.3m)(926.0k)125.0k(991.0k)(3.3m)(4.8m)(4.1m)

EBIT margin, %

(50%)(54%)(4%)(11%)(21%)(3%)(11%)(19%)5%(9%)(18%)(13%)(80%)(13%)(5%)(4%)(10%)(9%)(5%)(3%)0%(4%)(18%)(22%)(19%)

Interest expense

3.0m499.8k2.6m976.7k3.3m780.3k1.1k1.3k39.4k17.0k28.7k183.0k348.0k559.0k

Interest income

18.4k17.0k10.0k222.8k

Pre tax profit

2.8m697.2k(7.5m)(7.0m)(27.6m)(6.5m)(4.2m)(1.4m)(3.1m)(3.1m)(2.1m)(2.2m)(1.0m)(2.0m)(4.5m)(5.9m)(5.0m)

Income tax expense

32.2k(44.8k)94.5k12.0k21.0k71.0k131.0k7.0k28.0k76.0k14.0k69.0k34.0k(3.0k)10.0k26.0k53.0k

Net Income

(7.4m)116.3k(16.0m)6.2m(6.1m)(7.4m)(2.4m)(3.9m)2.7m408.3k602.6k(7.5m)(7.0m)(27.6m)(6.6m)(4.2m)(1.4m)(3.1m)(3.1m)(2.1m)(2.3m)(1.1m)(2.0m)(4.5m)(5.9m)(5.1m)

MusclePharm Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2019

Cash

659.8k5.4m1.0m7.1m4.9m6.2m1.5m

Accounts Receivable

2.6m3.3m13.7m16.6m22.0m16.7m4.8m

Prepaid Expenses

534.5k44.7k3.0m1.7m3.7m993.0k1.1m

Inventories

258.0k15.8m21.1m12.5m8.6m6.5m4.7m

Current Assets

4.0m4.9m44.5m46.4m47.3m28.8m30.5m12.2m

PP&E

907.5k1.4m2.6m7.8m6.7m3.2m1.8m216.0k

Total Assets

5.0m6.8m52.2m66.4m63.8m34.1m33.8m14.5m

Accounts Payable

9.4m11.7m28.4m27.8m39.7m9.6m11.7m26.2m

Short-term debt

1.3m4.5m2.6m8.0m3.0m3.0m10.6m

Current Liabilities

17.7m16.5m32.4m42.8m67.3m38.4m28.5m41.5m

Long-term debt

307.2k4.5k54.6k146.0k9.2m17.8m951.0k

Non-Current Liabilities

4.5k

Total Debt

1.6m4.5m2.5m8.2m3.0m3.0m11.5m

Total Liabilities

18.0m16.5m32.4m43.0m73.8m39.0m46.4m42.5m

Common Stock

605.9k2.8k9.3k14.0k14.0k14.0k31.0k

Additional Paid-in Capital

31.6m54.8m103.1m129.1m147.6m156.3m159.6m177.9m

Retained Earnings

(45.2m)(64.1m)(81.8m)(95.7m)(147.5m)(151.0m)(162.0m)(195.9m)

Total Equity

(13.0m)(9.8m)19.7m23.4m(10.1m)(4.9m)(12.5m)(28.0m)

Debt to Equity Ratio

-0.1 x0.1 x-0.3 x-0.2 x

Debt to Assets Ratio

0.3 x0 x0 x0.1 x

Financial Leverage

-0.4 x-0.7 x2.6 x2.8 x-6.3 x-7 x-2.7 x-0.5 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

517.8k1.3m292.0k634.9k8.5m8.7m5.7m3.3m3.8m2.9m4.8m4.2m3.5m9.1m13.1m5.9m3.0m3.6m4.9m5.1m2.4m1.7m613.0k1.1m1.5m

Accounts Receivable

2.4m3.6m4.5m2.1m4.0m8.0m9.2m10.9m19.6m19.2m23.2m19.0m24.6m15.6m22.3m20.2m15.9m15.2m13.4m13.1m16.9m16.3m16.2m5.5m7.2m5.2m

Prepaid Expenses

382.5k823.3k336.8k204.5k92.0k1.6m1.1m3.4m1.6m2.0m1.8m2.0m3.6m3.4m4.0m4.5m3.0m2.1m2.4m1.9m895.0k1.1m1.1m827.0k697.0k815.0k

Inventories

219.3k396.9k419.4k1.2m9.6m16.7m19.8m24.0m13.9m14.9m19.3m8.6m6.9m8.0m6.1m6.1m6.3m7.7m7.7m7.3m9.8m8.5m7.1m

Current Assets

3.3m4.7m6.4m3.0m5.8m19.0m21.7m34.4m49.0m49.2m59.0m45.8m53.2m45.2m45.2m44.8m32.9m26.6m25.6m26.3m30.8m27.5m26.4m16.8m17.5m14.6m

PP&E

514.4k903.6k1.1m1.3m1.5m1.4m1.3m1.7m5.5m6.2m7.3m7.5m7.6m7.0m6.4m3.9m3.3m2.9m2.5m2.2m1.6m1.5m576.0k433.0k355.0k280.0k

Total Assets

4.9m5.7m7.6m4.7m7.8m20.5m23.3m41.5m65.6m65.6m79.6m67.9m75.1m62.2m61.2m50.6m38.3m31.1m29.8m30.1m33.9m30.4m28.3m20.2m20.5m17.3m

Accounts Payable

2.9m4.7m7.8m5.2m10.1m7.7m8.2m16.5m24.3m23.9m28.1m28.8m37.8m40.4m39.4m39.1m36.1m10.9m9.1m9.4m14.9m16.6m20.7m19.9m24.4m27.9m

Short-term debt

2.0m1.0m1.2m(1.4m)(3.9m)76.7k74.3k70.5k2.6m45.6k8.1m9.3m7.3m5.9m21.0k11.0k11.0k3.9m2.0m2.0m1.5m24.7m25.7m8.2m

Current Liabilities

10.3m10.1m24.5m15.6m14.9m13.3m10.6m18.9m30.7m28.5m41.4m44.2m54.2m67.5m72.6m65.3m53.9m38.1m37.8m22.4m30.4m27.6m28.5m51.2m57.3m40.9m

Long-term debt

87.6k792.9k248.9k114.7k159.2k506.074.3k78.0k177.9k412.0k135.7k2.7m2.7m3.6m227.0k137.0k103.0k270.0k1.9m19.0m18.0m18.3m17.3m1.3m1.1m1.0m

Total Debt

2.1m1.8m1.4m(1.2m)(3.7m)77.2k74.3k148.5k2.5m91.2k91.2k12.1m6.0m2.6m3.0m3.0m3.0m270.0k1.9m22.9m2.0m2.0m1.5m26.0m26.8m9.2m

Total Liabilities

10.4m10.9m24.8m15.7m15.1m13.3m10.6m18.9m30.8m28.8m41.5m46.9m56.9m67.8m73.1m65.6m54.8m38.5m39.8m41.6m48.5m46.0m45.8m52.5m58.4m42.0m

Common Stock

252.6k354.4k1.4m1.4m2.3m6.8k7.8k8.9k10.5k10.8k11.3k14.0k14.0k14.0k14.0k14.0k14.0k14.0k14.0k14.0k14.0k15.0k15.0k15.0k15.0k31.0k

Additional Paid-in Capital

28.5m28.7m42.8m43.0m51.9m79.3m87.1m101.0m115.4m118.3m125.0m134.3m138.6m142.5m152.4m153.5m153.6m156.9m157.4m158.0m159.8m159.9m160.0m159.1m159.5m177.8m

Retained Earnings

(34.3m)(34.2m)(61.2m)(55.0m)(61.1m)(71.5m)(73.9m)(77.8m)(79.1m)(80.0m)(79.4m)(103.1m)(110.2m)(137.8m)(154.1m)(158.3m)(159.8m)(154.1m)(157.3m)(159.4m)(164.3m)(165.3m)(167.3m)(181.4m)(187.3m)(192.4m)

Total Equity

(5.6m)(5.1m)(17.2m)(11.0m)(7.3m)7.2m12.6m22.7m34.8m36.8m38.1m21.0m18.2m(5.5m)(11.9m)(15.0m)(16.4m)(7.4m)(10.0m)(11.5m)(14.6m)(15.6m)(17.5m)(32.4m)(37.8m)(24.6m)

Debt to Equity Ratio

-0.4 x-0.4 x0 x0 x0.1 x0 x0 x0.3 x-0.5 x-0.3 x-0.2 x-0.2 x-0.1 x-0.1 x-0.1 x

Debt to Assets Ratio

0.4 x0.3 x0 x0 x0 x0 x0 x0.1 x0 x0 x0.1 x0.1 x0.1 x0.1 x0.1 x

Financial Leverage

-0.9 x-1.1 x-0.4 x-0.4 x-1.1 x2.8 x1.8 x1.8 x1.9 x1.8 x2.1 x3.2 x4.1 x-11.2 x-5.2 x-3.4 x-2.3 x-4.2 x-3 x-2.6 x-2.3 x-1.9 x-1.6 x-0.6 x-0.5 x-0.7 x

MusclePharm Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(12.4m)(12.3m)(16.0m)(9.9m)(15.9m)(7.4m)(9.8m)(13.7m)2.7m1.8m2.4m(7.5m)(14.5m)(42.2m)(6.6m)(10.8m)(12.2m)(3.1m)(6.3m)(8.4m)(2.3m)(3.4m)(5.4m)(4.5m)(10.4m)(15.5m)

Depreciation and Amortization

31.4k89.4k89.7k199.8k325.2k161.3k3.8m10.3m1.4m2.8m4.1m607.0k1.3m2.1m647.0k1.2m1.7m420.0k790.0k1.1m387.0k558.0k822.0k196.0k354.0k509.0k

Accounts Receivable

(2.0m)(3.3m)(2.0m)502.2k(1.5m)(4.4m)(5.7m)(7.8m)(5.1m)(4.8m)(9.1m)(2.3m)(8.1m)890.0k(302.0k)952.0k5.1m(1.9m)(120.0k)(753.0k)(443.0k)(71.0k)(454.0k)557.0k(1.2m)1.1m

Inventories

(219.3k)(396.9k)9.0k86.9k(9.6m)(3.2m)(7.4m)7.2m6.2m487.0k2.3m1.4m59.0k2.5m2.5m2.4m(1.3m)(1.2m)(755.0k)3.7m4.8m6.2m

Accounts Payable

1.1m3.0m3.5m867.1k8.2m1.5m2.1m11.1m(2.3m)(2.7m)2.0m719.0k10.1m(14.9m)(591.0k)(1.2m)(4.9m)803.0k530.0k417.0k2.9m5.8m8.4m(5.2m)(527.0k)1.7m

Cash From Operating Activities

(2.6m)(4.1m)1.4m438.0k286.8k(3.2m)(5.2m)(8.0m)(784.8k)539.9k(5.5m)682.0k4.2m7.7m2.4m(686.0k)(486.0k)(1.0m)(1.8m)(2.3m)(232.0k)(39.0k)2.0m(4.8m)(5.3m)(4.2m)

Purchases of PP&E

(324.4k)(771.7k)(305.8k)(544.9k)(899.8k)(216.3k)(307.8k)(825.2k)(1.3m)(2.4m)(3.7m)(257.0k)(851.0k)(1.3m)(50.0k)(378.0k)(459.0k)(27.0k)(14.0k)(73.0k)(86.0k)(13.0k)(13.0k)(13.0k)

Cash From Investing Activities

(324.4k)(771.7k)(305.8k)(579.9k)(934.8k)(234.6k)(353.6k)(2.9m)(1.3m)315.6k(3.5m)(660.0k)(2.3m)(2.9m)(28.0k)5.5m5.4m(27.0k)(14.0k)(73.0k)(86.0k)(13.0k)(13.0k)(13.0k)

Short-term Borrowings

(2.5m)(16.9k)(4.0m)(6.0m)(14.5m)(3.0m)(3.0m)(3.0m)(1.0m)(1.0m)(1.5m)

Long-term Borrowings

(3.3m)(4.1m)(5.2m)(4.4m)(4.4m)(4.4m)(2.9k)(138.0k)(504.0k)(869.0k)(3.0m)(3.0m)(3.0m)(36.0k)(63.0k)(106.0k)(34.0k)(69.0k)(101.0k)(6.4m)(16.7m)(29.3m)

Cash From Financing Activities

3.4m4.8m(478.1k)(266.7k)615.5k11.9m14.2m16.7m(2.9k)(2.5m)6.6m3.8m1.5m(2.3m)(364.0k)1.2m(6.0m)(900.0k)403.0k2.1m(872.0k)(3.7m)(6.4m)3.1m4.1m3.5m

Net Change in Cash

474.1k(43.7k)639.5k(367.8k)(24.9k)8.5m8.7m5.7m(2.1m)(1.6m)(2.5m)3.8m3.2m2.4m2.0m6.0m(1.2m)(1.9m)(1.4m)(65.0k)(1.1m)(3.8m)(4.5m)(1.7m)(1.2m)(774.0k)

Interest Paid

2.5m101.7k265.1k423.7k501.2k410.5k410.8k35.8k52.8k78.8k124.0k270.0k384.0k439.0k926.0k1.2m672.0k1.1m1.8m614.0k1.9m2.7m440.0k562.0k1.2m

Income Taxes Paid

83.5k77.2k240.3k40.0k54.0k57.0k61.0k113.0k206.0k8.0k62.0k86.0k68.0k69.0k173.0k41.0k73.0k

MusclePharm Ratios

USDQ2, 2011

Debt/Equity

-0.4 x

Debt/Assets

0.4 x

Financial Leverage

-0.9 x

MusclePharm Employee Rating

2.121 votes
Culture & Values
2.3
Work/Life Balance
2.4
Senior Management
2.3
Salary & Benefits
2.6
Career Opportunities
2.4
Source